106 related articles for article (PubMed ID: 20400408)
1. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.
Cella D; Gilet H; Viala-Danten M; Peeters K; Dubois D; Martin S
HIV Clin Trials; 2010; 11(1):18-27. PubMed ID: 20400408
[TBL] [Abstract][Full Text] [Related]
2. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
[TBL] [Abstract][Full Text] [Related]
4. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.
Trottier B; Di Perri G; Madruga JV; Peeters M; Vingerhoets J; Picchio G; Woodfall BJ
HIV Clin Trials; 2010; 11(4):175-85. PubMed ID: 20974573
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
[TBL] [Abstract][Full Text] [Related]
6. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
7. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer G; Duvivier C; Rieger A; Durant J; Rey D; Schmidt W; Hill A; van Delft Y; Marks S;
J Antimicrob Chemother; 2012 Mar; 67(3):685-90. PubMed ID: 22210755
[TBL] [Abstract][Full Text] [Related]
8. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Clumeck N; Cahn P; Molina JM; Mills A; Nijs S; Vingerhoets J; Witek J
Int J STD AIDS; 2010 Nov; 21(11):738-40. PubMed ID: 21187353
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
[TBL] [Abstract][Full Text] [Related]
10. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.
Hill A; Grossman H; Cohen C; Nadler J; Peeters M
HIV Clin Trials; 2007; 8(2):68-76. PubMed ID: 17507322
[TBL] [Abstract][Full Text] [Related]
11. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.
Girard PM; Campbell TB; Grinsztejn B; Hartikainen J; Rachline A; Nijs S; Witek J
HIV Med; 2012 Aug; 13(7):427-35. PubMed ID: 22413938
[TBL] [Abstract][Full Text] [Related]
12. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lazzarin A; Campbell T; Clotet B; Johnson M; Katlama C; Moll A; Towner W; Trottier B; Peeters M; Vingerhoets J; de Smedt G; Baeten B; Beets G; Sinha R; Woodfall B;
Lancet; 2007 Jul; 370(9581):39-48. PubMed ID: 17617271
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
[TBL] [Abstract][Full Text] [Related]
15. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
[TBL] [Abstract][Full Text] [Related]
19. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
[TBL] [Abstract][Full Text] [Related]
20. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
